Update on Early Combination Therapy with Lastest Monoclonal Antibodies and Antivirals as HIV, HCV, Influenza in Extremely Vulnerable Persons with Sars-Cov-2: A Literature Review and Clinical Experience
Journal Title: Journal of Clinical Medical Research - Year 2025, Vol 6, Issue 1
Abstract
The emergence of new variants of concern in immunocompromised persons with SARS-CoV-2, particularly those with mutations in the spike protein, has complicated treatment strategies. Some Therapies focused only on viral clearance effects and not on major clinical outcomes. As the virus continues to evolve, the development of broad-spectrum therapies, along with personalized approaches to treatment, will be crucial in managing COVID-19 . After the first year period in which several treatments were employed early intervention strategies, including the use of antiretrovirals and monoclonal antibodies, have emerged as promising approaches to mitigate the severity of COVID-19 in fragile individuals and prevent disease progression, hospitalization and death even in recent time with less aggressive SARS-CoV-2 variants. Guidelines, high-quality data for combination treatment exploiting antivirals and neutralizing antibodies do not exist in the outpatient setting, especially in severe immunocompromised individuals. Nevertheless, several studies have attempted to investigate the efect of this approach and although these are often observational studies without control groups, generally no severe adverse reactions from the combination therapy have been reported. The potential efficacy of early combination therapy, based on an antiviral plus a monoclonal antibody, for COVID-19 in severely immunocompromised patients is matter of clinical and literature debate in the scientific word. To date, information concerning the early treatments of COVID-19 using combined therapies has been limited. In this Literature Review we explain the Last variant of concern and the updates on combination therapy for vulnerable persons with Sars-Cov-2.
Authors and Affiliations
Weimer LE1*, Cattari G2, Fanales Belasio E3, Cuccuru E2, Vidili G2
Keywords
Related Articles
- EP ID EP758354
- DOI https://doi.org/10.46889/JCMR.2025.6102
- Views 47
- Downloads 0
c-Kit – The Novel Receptor: Physiological Roles, Downstream Signaling and Implications in Cancer
The belief that adult mammalian heart lacks regenerative potential was challenged by the identification of c-kit positive Cardiac Progenitor Cells (CPCs) in the heart. SCIPIO; a phase I clinical trial; has shown that a...
Ageing: The Emerging Area of Bio-gerontology- A Review
Ageing is linked to a progressive loss of physical function and fitness, imperfect maintenance and repair systems. Many theories, such as evolutionary (mutations), telomere shortening, linked to a system (neuroendocrinol...
Clinical Examples of the Use of Mercureid Drug in Patients with Ischemic Neuropathy of the Optic Nerve That Appeared After Long COVID-19
Most people with coronavirus disease 2019 (COVID-19) recover completely within a few weeks. But some people continue to experience symptoms after the initial recovery. This condition is called post-COVID-19 syndrome or...
Creatine Derivative: Complete Relief of Itch by Topical Administration and Marked Control of Pruritic Dermatitis
Clinical tests and study reveal that the non-toxic creatine derivative, N-acetyl ethyl creatinate topically applied provides rapid and complete relief of itch of various kinds. The compound has been found to be therapeut...
Locoregional Treatments in Peritoneal Metastasis from Gastric Cancer
Peritoneal Metastasis (PM) is a common site of dissemination of gastric cancer. PM remains a major cause of mortality and is associated with poor prognosis. For this reason the last 30 years the treatment of peritoneal d...